Roberts Pharmaceutical
Executive Summary
Proprietary radiosensitizing agents will be screened by Dartmouth University Medical School under a research agreement with the firm. Roberts will provide funding for the in vivo and in vitro screening. Two compounds are expected to go into Phase I clinicals in 1989. Roberts' lead radiosensitizer, etanidazole, is in Phase III trials in the U.S. and Europe. Roberts licensed etanidazole from the National Cancer Institute and is in agreements for the product with DuPont and Chemie Linz AG.